Cuban researchers have discovered pharmacological evidence of the neuro-protective qualities of a new molecule called JM-20, opening up promising prospects for the treatment of cerebral ischemia, a serious global health problem.
This discovery now means that the next phase of clinical trails on humans can take place. If successful and the neuro-protective qualities of JM-20 are proven, this could lead to the creation of the first product with effective therapeutic properties to treat the condition and its associated effects. The molecule and its derivatives are protected under a 100% national patent.
Scientific entities involved in the study include the Medicines Development and Research Center’s (Cidem) Neuro-Protection Laboratory; the Research Center for Biological Investigations and Evaluations; the University of Havana’s (UH) Pharmacy and Food Institute; Organic Synthesis Laboratory at the UH’s Chemistry Faculty; Institute of Basic Sciences’ Biology department at Brazil’s Río Grande del Sur Federal University; and Cidem’s Histology Laboratory.
Winner of the 2015 Academy of Sciences of Cuba National Prize in the category of Biomedical Sciences, the study has also received a Special Award from Citma for the most important scientific result.